Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Public ClinicalTrials.gov record NCT02282020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.
Study identification
- NCT ID
- NCT02282020
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 266 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 6, 2015 (Actual)
- Primary completion
- Oct 10, 2018 (Actual)
- Completion
- Jul 19, 2022 (Actual)
- Last update posted
- Jul 26, 2022
2015 – 2022
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35233 | — |
| Research Site | Mobile | Alabama | 36604 | — |
| Research Site | Sacramento | California | 95817 | — |
| Research Site | San Francisco | California | 94118 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Littleton | Colorado | 80120 | — |
| Research Site | Hartford | Connecticut | 06106 | — |
| Research Site | Fort Gordon | Georgia | 30905 | — |
| Research Site | Covington | Louisiana | 70433 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Albany | New York | 12208 | — |
| Research Site | Mineola | New York | 11501 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Springfield | Oregon | 97477 | — |
| Research Site | Abington | Pennsylvania | 19001 | — |
| Research Site | Knoxville | Tennessee | 37920 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Bedford | Texas | 76022 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02282020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2022 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02282020 live on ClinicalTrials.gov.